Matthew W. Foehr Sells 41,811 Shares of OmniAb, Inc. (NASDAQ:OABI) Stock

OmniAb, Inc. (NASDAQ:OABI) CEO Matthew W. Foehr sold 41,811 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $3.24, for a total transaction of $135,467.64. Following the sale, the chief executive officer now directly owns 3,749,639 shares of the company’s stock, valued at approximately $12,148,830.36. This trade represents a 1.10 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

OmniAb Stock Performance

NASDAQ OABI opened at $3.20 on Friday. The company has a fifty day simple moving average of $3.66 and a 200 day simple moving average of $4.06. OmniAb, Inc. has a 12-month low of $3.11 and a 12-month high of $6.55. The company has a market cap of $451.89 million, a P/E ratio of -5.16 and a beta of -0.10.

Analyst Upgrades and Downgrades

OABI has been the subject of several recent analyst reports. Benchmark reaffirmed a “buy” rating and set a $8.00 price objective on shares of OmniAb in a research report on Thursday, November 14th. HC Wainwright reaffirmed a “buy” rating and set a $11.00 price objective on shares of OmniAb in a research report on Thursday, November 14th.

Institutional Trading of OmniAb

Several hedge funds have recently bought and sold shares of the business. Palumbo Wealth Management LLC grew its position in OmniAb by 12.5% in the 3rd quarter. Palumbo Wealth Management LLC now owns 24,640 shares of the company’s stock valued at $104,000 after purchasing an additional 2,744 shares during the period. Sei Investments Co. grew its position in OmniAb by 11.0% in the 2nd quarter. Sei Investments Co. now owns 29,024 shares of the company’s stock valued at $109,000 after purchasing an additional 2,888 shares during the period. SG Americas Securities LLC grew its position in OmniAb by 16.5% in the 4th quarter. SG Americas Securities LLC now owns 40,609 shares of the company’s stock valued at $144,000 after purchasing an additional 5,751 shares during the period. China Universal Asset Management Co. Ltd. grew its position in OmniAb by 64.5% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 22,727 shares of the company’s stock valued at $96,000 after purchasing an additional 8,909 shares during the period. Finally, Woodstock Corp grew its position in OmniAb by 1.2% in the 4th quarter. Woodstock Corp now owns 802,578 shares of the company’s stock valued at $2,841,000 after purchasing an additional 9,725 shares during the period. Institutional investors and hedge funds own 72.08% of the company’s stock.

About OmniAb

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.